Jack Nathan Medical Corp.

As of October 31, 2023, Jack Nathan Medical Corp. has 87.10M shares outstanding.

These figures are as of October 31, 2023. The price-to-sales ratio is 0.25, and the price-to-book ratio stands at -0.90.

These figures are as of October 31, 2023. The EV/Sales ratio of 0.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Jack Nathan Medical Corp. trades at an EV/FCF ratio of 13.21, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of October 31, 2023, Jack Nathan Medical Corp. maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -239.55, indicating conservative leverage, while an interest coverage ratio of -4.69 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended October 31, 2023. Return on assets (ROA) is negative at -78.29, reflecting losses generated across the asset base.

Over the twelve months ended October 31, 2023, Jack Nathan Medical Corp. posted a gross margin of 72.66, reflecting its pricing power and cost economics. The operating margin of -33.27 and net profit margin of -47.80 provide insight into operational efficiency.

These figures cover the twelve months ended October 31, 2023. Free cash flow yield is negative at -2.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -290.63, meaning Jack Nathan Medical Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Jack Nathan Medical Corp.'s most recent stock split took place on October 6, 2020 with a 3:1 split ratio.

As of October 31, 2023, Jack Nathan Medical Corp. has an Altman Z-Score of -3.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.